Endocrine Abstracts

Pituitary adenomas are present in ∼25% of autopsy samples, and recent studies have also suggested that clinically important pituitary adenomas are some 5 times more common than previously recognised. Acromegaly is almost always due to a sporadic growth-hormone secreting pituitary adenoma, but familial acromegaly has been reported occasionally. Linkage and loss of heterozygosity studies have shown that it is caused by a tumour suppressor gene located at 11q13; very recent...

This is the first prospective study to compare the efficacy and safety of medical therapy and surgery as primary therapy in acromegaly.A total of 104 patients with untreated acromegaly were enrolled. Eighty-one patients randomized to receive either octreotide LAR 20 mg (n=40) or surgery (n=41) completed the 48 weeks treatment period, and constituted the population used for this analysis, regardless of response to treatment.<p class="abs...

Introduction: LNSC has shown high sensitivity and specificity for the initial diagnosis of CD and detection of disease recurrence; however, the use of LNSC to monitor medical treatment of CD is not well established. The results of an exploratory analysis evaluating changes in LNSC in CD patients receiving long-acting pasireotide during a Phase III study (CSOM230G2304; Lacroix et al. Lancet Diabetes Endocrinol 2018) are reported here.Methods: Pat...

Background: Dopamine agonists (DA) are the treatment of choice of prolactinomas. Cabergoline is preferable to bromocriptine due to its greater effectiveness and better tolerabilitiy. However, up to 30–50% of male patients may persist with low levels of testosterone despite prolactin (PRL) normalization under DA therapy or the use of the maximum tolerated dose of DA. The aim of this prospective open study was to evaluate the efficacy of the SERM clomiphene citrate (CC) in ...

Background: Dopamine agonists are the mainstay of treatment for prolactinomas. Cabergoline (CAB) is preferable to bromocriptine due to its greater efficacy and better tolerability.Subjects and methods: The aim of this retrospective open trial was to evaluate the efficacy and tolerability of CAB in a cohort of 160 patients with prolactinomas routinely followed in Pernambuco Endocrine Research Center and Division of Endocrinology, Hospital das Clinicas, Fe...

Background: Growth hormone secreting pituitary gland adenomas specifically express somatostatin (SST)-2 and SST5 receptors. First-generation somatostatin analogs (octreotide and lanreotide) are the mainstay in the medical treatment of acromegaly, however the percentage of patients controlled with these drugs significantly varies in the different studies (20–70%). Many factors are involved in the resistance to SRL somatostatin analogs such as sst, AIP, E-cadherin, ZAC1, fi...

Long-acting somatostatin receptor ligands (LA-SRLs) are a first line medical treatment for acromegaly but require monthly parenteral administration. Paltusotine (CRN00808) is a nonpeptide, small molecule somatostatin type 2 (SST2) receptor agonist with high oral bioavailability (70%), suitable for once daily, oral dosing. The recently reported results of the ACROBAT Edge study (NCT03789656) suggest that patients with acromegaly treated with injected SRLs can switch to once dai...

Paltusotine is a once-daily, oral selective nonpeptide somatostatin receptor type 2 (SST2) agonist, which is in clinical development for the treatment of acromegaly. Maintenance of insulin-like growth factor 1 (IGF-1) control and toleration was demonstrated in phase 2 studies evaluating paltusotine in biochemically controlled (IGF-1 ≤1xULN) [ACROBAT Evolve (NCT03792555)] and uncontrolled (1> IGF-1 ≤2.5xULN) [ACROBAT Edge (NCT03789656)] patients with acromegaly ...

Paltusotine is a once-daily, oral, nonpeptide somatostatin receptor type 2 (SST2) specific agonist, in development for the treatment of acromegaly and neuroendocrine tumors. We report interim results from ACROBAT Advance (NCT04261712), an ongoing, multicenter, open-label, long-term extension study of paltusotine in subjects with acromegaly who previously completed either Phase 2 study ACROBAT Edge (NCT03789656) or Evolve (NCT03792555). ACROBAT Edge enrolled 47 subjects with el...

Objective and methods: Recent studies suggest that altered alternative splicing and, consequently, appearance of an abnormal splicing pattern and even of aberrant/oncogenic splicing-variants, represent a common molecular feature of most tumor pathologies, including Pituitary Neuroendocrine Tumors (PitNETs). However, the putative alteration, pathophysiological role and potential therapeutic utility of splicing machinery components [i.e. spliceosome-components (SCs) and splicing...